GlaxoSmithKline Drops Research On Otilimab In COVID-19

  • GlaxoSmithKline Plc GSK, in its Q3 earnings release, revealed that it is stopping the development of otilimab in COVID-19 in patients who are at least 70 years old. 
  • The Company decided because their already-approved monoclonal antibody Xevudy “plays an important role as a treatment for mild-to-moderate COVID-19 in high-risk adult and pediatric patients,” according to a company statement. 
  • In February, GSK revealed that a single dose of otilimab failed to improve the likelihood of being alive and free of respiratory failure 28 days later in patients with severe COVID-19-related pulmonary disease. 
  • While GSK is stopping work on COVID-19, it is continuing to study otilimab in rheumatoid arthritis. 
  • A phase 3 clinical trial in the indication is scheduled to deliver data in 2H of 2022.
  • Xevudy (sotrovimab) is the anti-SARS-CoV-2 antibody GSK is developing with Vir Biotechnology Inc VIR.
  • Related: Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug.
  • Price Action: GSK shares are up 0.39% at $40.34 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!